DioGenix, National Multiple Sclerosis Society deal
DioGenix said the society's Fast Forward LLC subsidiary will provide up to $500,000 as part of a sponsored research agreement to develop a blood test for multiple sclerosis. DioGenix will work to determine if its MSPrecise approach can be used when isolating B cells from blood samples. The MSPrecise assay now uses next-generation sequencing to measure DNA mutations found in rearranged immunoglobin genes in B cells isolated from cerebrospinal fluid. DioGenix is evaluating the assay in a trial in about 150 subjects who have or are at risk of developing MS. Fast Forward is a non-profit organization established to accelerate the development of MS treatments by connecting university-based MS research with private-sector drug development, and by funding small companies to develop new therapies and repurpose FDA-approved drugs as new MS treatments. ...